Jim Weissman is a life sciences industry veteran, bringing over 30 years of experience in various roles such as business and corporate development, general management, marketing, mergers and acquisitions, and new product planning and development.
Currently, he is the principal of JBW Consulting LLC, specializing in biotech consulting with a focus on business and corporate development, along with serving as an independent board member for Cerberus Therapeutics and Telesis Bio.
Previously, Jim held the positions of EVP, COO and CBO, at Dicerna Pharmaceuticals, where he played a key role in securing significant business development deals with major industry players such as Alexion, Alnylam, Boehringer Ingelheim, Lilly, Novo Nordisk, and Roche, leading to the company’s acquisition by Novo Nordisk in 2021. Before his tenure at Dicerna, he was the vice president of business development at MannKind Corporation. His earlier experience includes leadership roles in business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, Japan, and various commercial and leadership positions at Pharmacia Biotech across the USA, Sweden, Japan, and the UK.
Jim holds a Bachelor of Science degree from Bates College.
